Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: Angiotensin‐converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE‐inhibitors. We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73 m 2) who started an ACE‐inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90‐day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium‐sparing diuretics, and a high dose for the ACE‐inhibitor (lisinopril). The risk score separated high‐risk patients (top quintile, observed risk of 6.9%) from low‐risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE‐inhibitors. Conclusions: The risk score separated high‐risk patients (who may need more intensive laboratory monitoring) from low‐risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis and prognostic research: what, why, and how?
Moons, K. G. M., Royston, P., Vergouwe, Y., Grobbee, D. E., & Altman, D. G. (2009) · BMJ · doi:10.1136/bmj.b375 · Cited by 1,337
Prognosis and prognostic research: Developing a prognostic model
Royston, P., Moons, K. G. M., Altman, D. G., & Vergouwe, Y. (2009) · BMJ · doi:10.1136/bmj.b604 · Cited by 1,172
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101081 · Cited by 162 · cited 1×
“5 mmol/L; or, (2) diagnosis code for hyperkalemia.”
Cited by
Goldstein, B. A., Navar, A. M., Pencina, M. J., & Ioannidis, J. P. A. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw042 · Cited by 936
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181
“Although many of the risk characteristics have been previously identified, an existing risk score did not incorporate sex or potassium, one of the strongest observed risk factors.(24,25,29) In our study, male sex was also a risk factor for the development of hyperkalemia, potentially because of lower intake of potassi…”
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Metadata
- Authors
- Johnson, E. S., Weinstein, J. R., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., Anderson, S., & Smith, D. H.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2010-02-24
- Volume
- 19
- Issue
- 3
- Pages
- 266-272
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1988582819
- Cited by
- 46
- References
- 4
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. https://app.cochat.ai/papers/10.1002/pds.1923
- The paper
- Johnson, E. S., Weinstein, J. R., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., Anderson, S., & Smith, D. H. (2010). Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.1923
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.